OncLive® On Air
Episodes
S11 Ep22: FDA Approval Insights: Vorasidenib in IDH1/2+ Grade 2 Astrocytoma and Oligodendroglioma
10 Oct 2024
Contributed by Lukas
In today’s episode, supported by Servier Pharmaceuticals, we had the pleasure of speaking with Jennie W. Taylor, MD, MPH, about the FDA approval of ...
S11 Ep21: Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD
07 Oct 2024
Contributed by Lukas
In our exclusive interview, Dr Dietrich discussed key efficacy findings from the 18-month follow-up of the phase 2 VISION trial (NCT02864992), which e...
S11 Ep20: FDA Approval Insights: Perioperative Durvalumab for Resectable NSCLC
03 Oct 2024
Contributed by Lukas
In today’s episode, supported by AstraZeneca, we had the pleasure of speaking with Sandip P. Patel, MD, and Brendon M. Stiles, MD, about the FDA a...
S11 Ep19: Immunotherapy Advances Expand the SCLC Treatment Paradigm: With Chandler Park, MD, and Tejas Patil, MD
02 Oct 2024
Contributed by Lukas
In part 2 of this 3-part Oncology Unplugged series, Chandler Park, MD, a genitourinary medical oncologist at Norton Cancer Institute in Louisville, Ke...
S11 Ep18: Board Review Resources 2024
30 Sep 2024
Contributed by Lukas
Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hema...
S11 Ep17: How Luspatercept Could Shake Up MDS Management—With Rory Shallis, MD
26 Sep 2024
Contributed by Lukas
In today’s episode, we had the pleasure of speaking with Rory Shallis, MD, an assistant professor of medicine and hematology at Yale School of Med...
S11 Ep16: FDA Approval Insights: Afami-Cel for Pretreated, Unresectable or Metastatic Synovial Sarcoma
23 Sep 2024
Contributed by Lukas
Dr Warner discusses the FDA approval of afami-cel for patients with advanced synovial sarcoma and key findings from the pivotal SPEARHEAD-1 trial.
S11 Ep15: Thomas and Lukas Highlight Updates in Brain Cancer from the 2024 ASCO Annual Meeting
19 Sep 2024
Contributed by Lukas
Welcome to OncLive On Air®! I’m your host today, Ashling Wahner. OncLive On Air is a podcast from OncLive®, which provides oncology profession...
S11 Ep14: Park and Patil Explore Advances in EGFR + NSCLC From ASCO 2024
18 Sep 2024
Contributed by Lukas
In Oncology Unplugged, a podcast series from MedNews Week, host Chandler Park, MD, a genitourinary medical oncologist at the Norton Cancer Institute i...
S11 Ep13: FDA Approval Insights: Epcoritamab in Relapsed/Refractory Follicular Lymphoma
16 Sep 2024
Contributed by Lukas
Welcome to OncLive On Air®! I’m your host today, Ashling Wahner. OncLive On Air is a podcast from OncLive®, which provides oncology professi...
S11 Ep12: Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress
11 Sep 2024
Contributed by Lukas
In today’s episode, we invited experts from across oncology specialties to discuss the abstracts and presentations they are most looking forward t...
S11 Ep11: Heme & Onc Fellow Board Review Tips 2024
09 Sep 2024
Contributed by Lukas
Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hema...
S11 Ep10: Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions
05 Sep 2024
Contributed by Lukas
In today’s episode, we had the pleasure of speaking with Narjust Florez, MD, about patient-focused lung cancer biomarker testing discussions.
S11 Ep9: Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer
04 Sep 2024
Contributed by Lukas
Drs Park and Graff discuss the evolution of treatment for patients with metastatic HR-positive breast cancer, including the role of CDK4/6 inhibitors.
S11 Ep8: Salgia Summarizes the Benefits of Tepotinib in MET Exon 14–Mutated NSCLC
02 Sep 2024
Contributed by Lukas
Dr Salgia discusses how he chooses between tepotinib and capmatinib in patients with stage IV NSCLC harboring MET exon 14 skipping mutations.
S11 Ep7: Chiang Contextualizes the Optimal Use of Lurbinectedin in SCLC Management
29 Aug 2024
Contributed by Lukas
Dr Chiang discusses the use of lurbinectedin in small cell lung cancer and tips for managing toxicities associated with this agent.
S11 Ep6: FDA Approval Insights: Dostarlimab Plus Chemotherapy in Advanced/Recurrent Endometrial Cancer
26 Aug 2024
Contributed by Lukas
Dr Tewari discusses the FDA approval of dostarlimab plus chemotherapy for patients with primary advanced or recurrent endometrial cancer.
S11 Ep5: Jhaveri on the INAVO120 Trial of Inavolisib/Palbociclib/Fulvestrant in PIK3CA -Mutant, HR+ Breast Cancer
22 Aug 2024
Contributed by Lukas
Dr Jhaveri discusses the INAVO120 trial of inavolisib plus palbociclib and fulvestrant in PIK3CA-mutant, HR-positive metastatic breast cancer.
S11 Ep4: Park and Kasi Expand on Perioperative Immunotherapy Updates in CRC
21 Aug 2024
Contributed by Lukas
Drs Park and Kasi delve into the shift toward neoadjuvant immunotherapy and the use of ctDNA as a prognostic tool in colorectal cancer.
S11 Ep3: Garcia-Manero on MDS Treatment Updates With Luspatercept and Beyond
19 Aug 2024
Contributed by Lukas
Dr Garcia-Manero discusses findings from research in myelodysplastic syndromes that were presented at the 2024 EHA Congress.
S11 Ep3: FDA Approval Insights: Durvalumab/Chemotherapy in dMMR Advanced Endometrial Cancer
15 Aug 2024
Contributed by Lukas
Dr Westin discusses the FDA approval of durvalumab plus chemotherapy for patients with dMMR advanced or recurrent endometrial cancer.
S11 Ep2: ASCO 2024 Plenary: NADINA Trial Neoadjuvant Ipi/Nivo vs Adjuvant Nivo for Resectable Stage III Melanoma
12 Aug 2024
Contributed by Lukas
Drs Armstrong and Tawagi discuss the NADINA trial of neoadjuvant nivolumab/ipilimumab vs adjuvant nivolumab in resectable, macroscopic, stage III mela...
S11 Ep1: Rotow Reviews Key Updates on the Management of CNS Metastases in NSCLC
08 Aug 2024
Contributed by Lukas
Dr Rotow discusses data that demonstrated the central nervous system activity of datopotamab deruxtecan and osimertinib in patients with NSCLC.
S10 Ep50: Park and Grivas Expand on Treatment Updates in Bladder Cancer
07 Aug 2024
Contributed by Lukas
Drs Park and Grivas discuss bladder cancer treatment updates, including results from the SunRISe-1 trial of TAR-200 plus cetrelimab in NMIBC.
S10 Ep49: Halmos on the AE Profiles of Dato-DXd and Other ADCs in NSCLC
05 Aug 2024
Contributed by Lukas
Dr Halmos discusses common AEs associated with the ADCs that are used in NSCLC and ways to manage and mitigate these toxicities.
S10 Ep48: Lisberg Lends Insight About the TROPION-Lung01 Trial of Dato-DXd in NSCLC
01 Aug 2024
Contributed by Lukas
Dr Lisberg discusses key findings from the TROPION-Lung01 trial of Dato-DXd in patients with previously treated advanced or metastatic NSCLC.
S10 Ep47: Pegram Details the Use of Oral SERDs in ESR1+ Metastatic Breast Cancer
29 Jul 2024
Contributed by Lukas
S10 Ep47: Miller Discusses the Use of Selinexor in TP53 Wild-Type Advanced Endometrial Cancer
25 Jul 2024
Contributed by Lukas
Dr Miller discusses findings from the SIENDO trial of selinexor maintenance therapy in patients with TP53 wild-type advanced endometrial cancer.
S10 Ep46: Park and Sonpavde on Sacituzumab Govitecan Plus Enfortumab Vedotin in Metastatic Urothelial Cancer
24 Jul 2024
Contributed by Lukas
Drs Park and Sonpavde discuss findings from the phase 1 DAD trial, as well as a schema for the frontline management of metastatic urothelial carcinoma...
S10 Ep45: Bui and Kelly Discuss the Utility of Nab-Sirolimus in Advanced Malignant PEComa
18 Jul 2024
Contributed by Lukas
Drs Bui and Kelly discuss key long-term findings from the AMPECT trial investigating nab-sirolimus in patients with advanced malignant PEComa.
S10 Ep44: Curigliano on the DESTINY-Breast06 Trial in HER2-Low and -Ultralow Metastatic Breast Cancer
15 Jul 2024
Contributed by Lukas
Dr Curigliano discusses the DESTINY-Breast06 trial of trastuzumab deruxtecan in patients with HER2-low or HER2-ultralow metastatic breast cancer.
S10 Ep43: Orlowski on Isa-VRd in Transplant-Ineligible Multiple Myeloma
11 Jul 2024
Contributed by Lukas
Dr Orlowski discusses key efficacy data from the IMROZ trial of Isa-VRd in newly diagnosed, transplant-ineligible multiple myeloma.
S10 Ep42: Park and Sonpavde on Nivolumab Plus Gemcitabine/Cisplatin in Cisplatin-Eligible Urothelial Cancer
10 Jul 2024
Contributed by Lukas
Drs Park and Sonpavde discuss the CheckMate901 trial, which showed survival improvements with nivolumab plus chemotherapy in metastatic urothelial can...
S10 Ep41: ASCO 2024 Plenary: ADRIATIC Trial in Limited-Stage Small Cell Lung Cancer
08 Jul 2024
Contributed by Lukas
OncLive On Air partners with Two Onc Docs to bring insights on the ADRIATIC trial, data from which were presented at the 2024 ASCO Annual Meeting.
S10 Ep40: FDA Approval Insights: Imetelstat in Lower-Risk MDS and Transfusion-Dependent Anemia
01 Jul 2024
Contributed by Lukas
Dr Sekeres discusses the significance of the FDA approval of imetelstat for patients with lower-risk MDS and transfusion-dependent anemia.
S10 Ep39: Dietrich and Shiller Dive Into the Importance of Oncology Reflex Testing
27 Jun 2024
Contributed by Lukas
Drs Dietrich and Shiller detail the importance of collaboration between medical oncologists and pathologists to ensure beneficial oncology reflex test...
S10 Ep38: Agulnik Highlights Key Updates in GIST Research and Management
24 Jun 2024
Contributed by Lukas
Dr Agulnik spotlights key updates from across the GIST landscape ahead of GIST Awareness Day on July 13.
S10 Ep37: Reckamp Discusses the Integration of Pragmatic Elements Into Oncology Clinical Trial Designs
20 Jun 2024
Contributed by Lukas
Dr Reckamp discusses the definition of pragmatic clinical trials and ways that clinical trial investigators can make their research more pragmatic.
S10 Ep36: Rosenberg Reviews the Evolving Role of Toripalimab in Nasopharyngeal Carcinoma
17 Jun 2024
Contributed by Lukas
Dr Rosenberg discusses current standard strategies for treating patients with nasopharyngeal cancer, the evolving role of toripalimab in this treatmen...
S10 Ep35: ASCO 2024 Plenary: LAURA Trial in Unresectable Stage III EGFRm NSCLC
10 Jun 2024
Contributed by Lukas
OncLive On Air partners with Two Onc Docs to bring insights on primary data from the LAURA trial, which were presented at the 2024 ASCO Annual Meeting...
S10 Ep35: Paik Provides Insights Into Tepotinib Treatment in NSCLC Harboring MET Exon 14 Skipping Alterations
06 Jun 2024
Contributed by Lukas
Dr Paik discusses key findings from the phase 2 VISION trial investigating frontline tepotinib in patients with NSCLC harboring MET exon 14 skipping a...
S10 Ep34: Lenz Discusses the Prognostic and Predictive Value of HER2 Gene Expression in KRAS Wild-Type mCRC
03 Jun 2024
Contributed by Lukas
Lenz discusses the link between HER2 expression and responses with mCRC treatment regimens and how HER2 expression can guide treatment decision-making...
S10 Ep33: Levy Lends Insights Into the Current and Future Use of ADCs in NSCLC
30 May 2024
Contributed by Lukas
Dr Levy discusses the indication for trastuzumab deruxtecan in HER2+ NSCLC, other ADCs in development, and where the future of ADCs in NSCLC is headed...
S10 Ep33: Park and Sonpavde on Considerations for Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer
30 May 2024
Contributed by Lukas
Drs Park and Sonpavde emphasize their insights on the topline data from the EV-302 trial, considerations for community oncologists when deciding wheth...
S10 Ep32: Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
23 May 2024
Contributed by Lukas
Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ASCO Annual Meeti...
S10 Ep31: Ganjoo Discusses Treatment Plans, Patient Conversations, and the Role of Nab-Sirolimus in Malignant PEComa
20 May 2024
Contributed by Lukas
Dr Ganjoo discusses unmet needs for patients with malignant PEComa, treatment plan considerations, and the use of nab-sirolimus in this disease.
S10 Ep30: Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer
13 May 2024
Contributed by Lukas
Dr Brown discusses the rationale for the RAMP-301 trial of avutometinib plus defactinib in low-grade serous ovarian cancer.
S10 Ep30: Kummar on the Investigation of Rezatapopt in TP53 Y220C–Mutated Advanced Solid Tumors
09 May 2024
Contributed by Lukas
Dr Kummar discusses the significance of targeting TP53 Y220C in solid tumors and early data reported with rezatapopt in TP53 Y220C–mutant solid tumo...
S10 Ep30: Goy Gives Insights Into the Future Management of Lymphoma and Multiple Myeloma
06 May 2024
Contributed by Lukas
Dr Goy discusses the impact of CAR T-cell therapy on the lymphoma and multiple myeloma treatment paradigms and his anticipations for the future of hem...
S10 Ep29: Merkow and Connell Highlight Considerations for HAI Pump Use in CRC
02 May 2024
Contributed by Lukas
Drs Merkow and Connell discuss reasons why they adopted HAI therapy as a treatment offering for patients with CRC, characteristics of patients who are...
S10 Ep28: Bou Farhat and Nassar on the Use of NGS Mutation Signature vs IHC for Identifying dMMR Tumors
29 Apr 2024
Contributed by Lukas
Drs Nassar and Bou Farhat explain how tumor-only NGS could address the limitations of IHC testing for MMR mutation signatures across several tumor typ...
S10 Ep27: FDA Approval Insights: Cilta-Cel in R/R Myeloma After at Least 1 Prior Line of Therapy
22 Apr 2024
Contributed by Lukas
Dr Usmani details the FDA approval of cilta-cel for patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of ther...
S10 Ep26: Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin Lymphoma
18 Apr 2024
Contributed by Lukas
Drs Lunning and Rutherford discuss findings from the ECHELON-1 trial of BV-AVD in the cohort of patients with Hodgkin lymphoma over 60 years of age.
S10 Ep25: Breast Cancer Experts Share Obstacles and Successes as Women in Oncology
11 Apr 2024
Contributed by Lukas
Drs Graff, Mahtani, McCann, and Rugo shared moments throughout their lives and careers that sparked their interest in oncology, setbacks they overcame...
S1 Ep18: FDA Approval Insights: Ponatinib in Ph+ ALL
08 Apr 2024
Contributed by Lukas
Dr Jabbour expands on the multiple milestones achieved through ponatinib’s FDA approval for patients with Ph-positive ALL; the agent’s potency and...
S10 Ep24: Schmid Summarizes Updates in HER2-Positive Breast Cancer Management
01 Apr 2024
Contributed by Lukas
Dr Schmid discusses considerations for applying recent data updates in HER2-positive breast cancer management to clinical practice.
S10 Ep23: Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa
28 Mar 2024
Contributed by Lukas
Dr Wagner discusses current unmet needs for patients with PEComa, how ongoing research aims to address some of these gaps, and how findings from the A...
S10 Ep22: CRC Experts Highlight AE Management and Prevention Strategies for TAS-102/Bevacizumab, Regorafenib, and Fruquintinib
25 Mar 2024
Contributed by Lukas
Strickler, Leung, Dasari, and O'Neill discuss adverse effect monitoring and management with standard agents for patients with colorectal cancer.
S10 Ep21: Bagley Summarizes the ACTION trial of ONC201 in H3 K27M–Mutant Diffuse Midline Gliomas
21 Mar 2024
Contributed by Lukas
Dr Bagley discusses the evaluation of the small molecule ONC201 in the phase 3 ACTION trial in H3 K27M–mutant diffuse midline gliomas.
S10 Ep20: Lunning and Herrera Highlight Frontline Hodgkin Lymphoma Management Strategies
18 Mar 2024
Contributed by Lukas
Dr Lunning sits down with Alex Herrera, MD, of City of Hope, to discuss the frontline management of Hodgkin lymphoma, including the rationale for the ...
S10 Ep19: FDA Approval Insights: NALIRIFOX in Metastatic Pancreatic Cancer
11 Mar 2024
Contributed by Lukas
Dr Wainberg discusses the FDA approval of first-line NALIRIFOX for patients with metastatic pancreatic adenocarcinoma, key data from NAPOLI 3, and the...
S10 Ep18: Dr Kyriakopoulos on the Investigation of Masofaniten Plus Enzalutamide in mCRPC
07 Mar 2024
Contributed by Lukas
Dr Kyriakopoulos sheds light on the potential synergy and pharmacokinetic interactions between masofaniten and enzalutamide when used in combination f...
S10 Ep17: Kang Highlights Considerations for the Integration of Toripalimab into Nasopharyngeal Carcinoma Clinical Practice
29 Feb 2024
Contributed by Lukas
Dr Kang discusses the significance of the FDA approval of toripalimab for nasopharyngeal carcinoma, his anticipated use of the agent since its inclusi...
S10 Ep16: Mims Expands on the Evaluation of Emavusertib in the TakeAim Leukemia Trial of AML and MDS
26 Feb 2024
Contributed by Lukas
Dr Mims discusses the utility of emavusertib in acute myeloid leukemia and myelodysplastic syndrome and the rationale for the TakeAim Leukemia trial.
S10 Ep15: Tripathy Talks Through the Enduring Impact of the Miami Breast Cancer Conference
22 Feb 2024
Contributed by Lukas
Dr Tripathy discusses aspects of the Miami Breast Cancer Conference that stood out to him during his first time speaking at the meeting, ways that Mia...
S10 Ep14: Kitco and Patel Emphasize the Importance of GVHD Research and Awareness
19 Feb 2024
Contributed by Lukas
Drs Kitko and Patel discuss graft-versus-host disease recognition, treatment selection, and ongoing research with novel agents and biomarkers of respo...
S10 Ep13: FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced/Metastatic Urothelial Carcinoma
12 Feb 2024
Contributed by Lukas
Dr Galsky discusses the FDA approval of enfortumab vedotin plus pembrolizumab for patients with locally advanced or metastatic urothelial cancer, key ...
S10 Ep12: Community Oncologists on the Importance of Self-Reliance and Collegial Trust as Women in Medicine
08 Feb 2024
Contributed by Lukas
Drs Jacob, Van Der Wall, and Wright-Browne discuss challenges related to gender bias that they have faced throughout their careers, growth opportuniti...
S10 Ep11: Lunning and Brander Emphasize the Importance of Early CLL Diagnosis and Treatment
05 Feb 2024
Contributed by Lukas
Drs Lunning and Brander discuss the evolution of chronic lymphocytic leukemia management.
S10 Ep10: Expert and Patient Perspectives on AE Management With FGFR Inhibitors in Cholangiocarcinoma
29 Jan 2024
Contributed by Lukas
Goyal, Bishop, Kelley, and Kuhlman discuss ways to prepare patients with cholangiocarcinoma for FGFR inhibitor–related adverse effects.
S10 Ep9: FDA Approval Insights: Pirtobrutunib in Previously Treated CLL/SLL
25 Jan 2024
Contributed by Lukas
Dr Davids discusses the FDA approval of pirtobrutinib for patients with previously treated CLL/SLL; key efficacy and safety data from the BRUIN trial;...
S10 Ep8: Lunning and Maddocks Talk Through Frontline MCL Management
22 Jan 2024
Contributed by Lukas
Dr Lunning sits down with Kami J. Maddocks, MD, of The Ohio State University Comprehensive Cancer Center––James, to discuss the management of MCL ...
S10 Ep7: FDA Approval Insights: Nirogacestat in Progressing Desmoid Tumors Requiring Systemic Treatment
15 Jan 2024
Contributed by Lukas
Dr Kasper discusses the FDA approval of nirogacestat for patients with progressing desmoid tumors; key efficacy, safety, and quality-of-life outcomes ...
S10 Ep6: Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers
11 Jan 2024
Contributed by Lukas
Drs Monk and Tarantino highlight current research investigating B7-H4–directed ADCs in multiple solid tumor types; other promising ADCs in developme...
S10 Ep5: Donington and Stiles Summarize NSCLC Resectability Parameters and Multidisciplinary Management
08 Jan 2024
Contributed by Lukas
Drs Donington and Stiles discuss the implications of perioperative immunotherapy trials on early-stage lung cancer management, definitions of resectab...
S10 Ep4: FDA Approval Insights: Capivasertib Plus Fulvestrant in Advanced HR+/HER2- Breast Cancer With PIK3CA, AKT1, or PTEN Alterations
04 Jan 2024
Contributed by Lukas
Dr Gradishar discusses the FDA approval of capivasertib plus fulvestrant for patients with advanced HR-positive, HER2-negative breast cancer harboring...
S10 Ep3: Santos Summarizes Key Updates From EMPOWER-Lung 1 and EMPOWER-Lung 3 With Cemiplimab in NSCLC
01 Jan 2024
Contributed by Lukas
Dr Santos discusses findings from the EMPOWER-Lung 3 trial of cemiplimab plus chemotherapy in patients with advanced non–small cell lung cancer, as ...
S10 Ep2: Jabbour Reports Top Takeaways From ASH 2023 of Olverembatinib in CML and ALL
28 Dec 2023
Contributed by Lukas
Dr Jabbour discusses the activity and the utilization of olverembatinib in chronic myeloid leukemia and expanded upon the role that TKIs can play in t...
S10 Ep1: Eskander Emphasizes the Importance of Inclusivity and Accessibility in Oncology Clinical Trials
25 Dec 2023
Contributed by Lukas
Dr Eskander discusses the impact of social determinants of health on cancer clinical trial participation; effective strategies for considering and eng...
S9 Ep50: Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL
21 Dec 2023
Contributed by Lukas
Dr Lunning and Neha Mehta-Shah, MD, MSCI, of Washington University School of Medicine, highlight challenges that arise when diagnosing patients with P...
S9 Ep49: Simeone and Fakih Detail Research Objectives With A2B530 in CEA-Expressing Solid Tumors
18 Dec 2023
Contributed by Lukas
Drs Simeone and Fakih discuss the main objective and design of the observational BASECAMP-1 study and how it functions alongside the EVEREST-1 study, ...
S9 Ep48: Donington and Stiles Describe the Surgical Implications of Lung Cancer Treatment Evolutions
11 Dec 2023
Contributed by Lukas
Drs Donington and Stiles discuss how the findings from the ADAURA trial with adjuvant osimertinib have changed thoracic surgery expectations, the pote...
S9 Ep47: Abdou Spotlights Factors Influencing ADC Treatment Selection in Breast Cancer
07 Dec 2023
Contributed by Lukas
Dr Abdou discusses how characteristics of patients with breast cancer impact ADC treatment selection and highlights some of the topline takeaways from...
S9 Ep46: FDA Approval Insights: Toripalimab in Recurrent/Metastatic Nasopharyngeal Carcinoma
04 Dec 2023
Contributed by Lukas
Drs Hanna and Kandula discuss the significance of the FDA approval of toripalimab in nasopharyngeal carcinoma; pivotal data from the JUPITER-02 and PO...
S9 Ep45: Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma
30 Nov 2023
Contributed by Lukas
Dr Lunning sits down with Caron A. Jacobson, MD, MMSc, or Dana-Farber Cancer Institute, to discuss the characteristics of FL that may prompt aggressiv...
S9 Ep44: Dumbrava Details Ongoing Research With PC14586 in p53 Y220C–Mutated Advanced Solid Tumors
23 Nov 2023
Contributed by Lukas
Dr Dumbrava discusses the rationale and design of the PYNNACLE trial; phase 1 efficacy and safety findings with PC14586 in patients with p53 Y220C–m...
S9 Ep43: FDA Approval Insights: Ivosidenib in R/R IDH1+ Myelodysplastic Syndrome
20 Nov 2023
Contributed by Lukas
Dr DiNardo discusses the the FDA approval of ivosidenib for patients with relapsed/refractory IDH1-mutant myelodysplastic syndromes, the unique mechan...
S9 Ep42: Halmos Highlights Evaluation of the EGFR Inhibitor BDTX-1535 in NSCLC
16 Nov 2023
Contributed by Lukas
Dr Halmos discusses the ongoing investigation of the potent, selective, and irreversible EGFR inhibitor BDTX-1535 in patients with non–small cell lu...
S9 Ep41: Feigin Discusses the Association Between Benzodiazepines and Pancreatic Cancer Outcomes
13 Nov 2023
Contributed by Lukas
Dr Feigin discusses findings from a study on the varying effects of the benzodiazepines lorazepam and alprazolam on PFS outcomes for patients with pan...
S9 Ep40: Khouri Highlights the Ongoing AFFIRM-AL Trial in AL Amyloidosis
09 Nov 2023
Contributed by Lukas
Dr Khouri discusses unmet needs in AL amyloidosis, the potential for birtamimab to become a new frontline standard of care beyond daratumumab, and the...
S9 Ep39: FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma
06 Nov 2023
Contributed by Lukas
Dr Weber discusses the FDA approval of adjuvant nivolumab for patients with completely resected stage IIB/C melanoma, key efficacy data from the Check...
S9 Ep38: Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma
30 Oct 2023
Contributed by Lukas
Drs Lunning and Nastoupil discuss the ins and outs of diagnostic workups for patients with follicular lymphoma; how to discern which patients may bene...
S9 Ep37: Naumann Discusses Notable Research Efforts in Endometrial Cancer
26 Oct 2023
Contributed by Lukas
Dr Naumann discusses the role of frontline maintenance therapy for patients with endometrial cancer; which patients are likely to benefit from the RUB...
S9 Ep36: Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection
23 Oct 2023
Contributed by Lukas
Dr Keshava discusses the rationale behind lung nodule programs, common barriers to implementing these programs, and how multidisciplinary collaboratio...
S9 Ep35: Hasanuma Highlights the Benefits of Building Authentic Connections Through Mentorship
19 Oct 2023
Contributed by Lukas
Dr Hasunuma shares that the objective of mentorship is to foster care, trust, and respect in mentor-mentee relationships and create authentic connecti...
S9 Ep34: FDA Approval Insights: Momelotinib in Myelofibrosis With Anemia
16 Oct 2023
Contributed by Lukas
Dr Kuykendall discusses the FDA approval of momelotinib in myelofibrosis with anemia, key data from the MOMENTUM trial, and how momelotinib alters the...
S9 Ep33: Gutierrez and Leslie Discuss Recent Efforts and Future Advances in CAR T-Cell Therapy
12 Oct 2023
Contributed by Lukas
Drs Gutierrez and Leslie discuss common barriers that institutions face when implementing CAR T-cell therapy programs, the early success story of outp...
S9 Ep32: Expert Insights on the United States Chemotherapy Shortage
09 Oct 2023
Contributed by Lukas
Oncology experts discuss the platinum chemotherapy shortage in the United States.
S9 Ep31: FDA Approval Insights: First-Line Luspatercept for Anemia in Lower-Risk MDS
05 Oct 2023
Contributed by Lukas
Dr Platzbecker discusses the FDA approval of luspatercept in lower-risk MDS with anemia; key efficacy and safety data from the COMMANDS trial; and how...
S9 Ep30: Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma
02 Oct 2023
Contributed by Lukas
Dr Richardson discusses the background of mezigdomide, key efficacy and safety findings with the agent plus dexamethasone in patients with relapsed/re...